{"protocolSection":{"identificationModule":{"nctId":"NCT05277311","orgStudyIdInfo":{"id":"HX-DZM-202119"},"organization":{"fullName":"Dongzhimen Hospital, Beijing","class":"OTHER"},"briefTitle":"Efficacy and Safety of LongShengZhi Capsule on Functional Recovery After Acute Ischaemic Stroke (LONGAN)","officialTitle":"Efficacy and Safety of LongShengZhi Capsule on Functional Recovery After Acute Ischaemic Stroke (LONGAN): A Randomized, Double-Blind, Placebo-Controlled Trial"},"statusModule":{"statusVerifiedDate":"2022-03","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-05-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2023-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-02-08","studyFirstSubmitQcDate":"2022-03-09","studyFirstPostDateStruct":{"date":"2022-03-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-03-09","lastUpdatePostDateStruct":{"date":"2022-03-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ying Gao","investigatorTitle":"Professor","investigatorAffiliation":"Dongzhimen Hospital, Beijing"},"leadSponsor":{"name":"Dongzhimen Hospital, Beijing","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The aim of the study is to determine if LongShengZhi Capsule is effective and safe in patients with ischemic stroke in comparison to placebo. This trial is a prospective, multicenter, randomized, placebo-controlled, double-blinded, parallel-group, superiority trial."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["ischemic stroke","LongShengZhi capsule","efficacy","safety","randomized controlled trial"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1376,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"LongShengZhi capsule","type":"EXPERIMENTAL","description":"Experimental group","interventionNames":["Drug: LongShengZhi capsule"]},{"label":"LongShengZhi capsule placebo","type":"PLACEBO_COMPARATOR","description":"Placebo group","interventionNames":["Drug: LongShengZhi capsule placebo"]}],"interventions":[{"type":"DRUG","name":"LongShengZhi capsule","description":"LongShengZhi capsules, orally, 5 capsules each time, three times a day.","armGroupLabels":["LongShengZhi capsule"]},{"type":"DRUG","name":"LongShengZhi capsule placebo","description":"LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.","armGroupLabels":["LongShengZhi capsule placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The proportion of patients with excellent outcome","description":"Excellent outcome defined as a modified Rankin scale (mRS) score ≤ 1 (scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death).","timeFrame":"90 days after randomization"}],"secondaryOutcomes":[{"measure":"Distribution of the modified Rankin scale (mRS) scores","description":"Modified Rankin scale (mRS) scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death.","timeFrame":"30 days after randomization"},{"measure":"Distribution of the modified Rankin scale (mRS) scores","description":"Modified Rankin scale (mRS) scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death.","timeFrame":"90 days after randomization"},{"measure":"The proportion of patients with good outcome","description":"Good outcome defined as a modified Rankin scale (mRS) score ≤2(scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death).","timeFrame":"30 days after randomization"},{"measure":"The proportion of patients with good outcome","description":"Good outcome defined as a modified Rankin scale (mRS) score ≤2(scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death).","timeFrame":"90 days after randomization"},{"measure":"Changes in National Institutes of Health Stroke Scale (NIHSS) scores","description":"Difference of NIHSS scores (range =0-42, with higher scores indicating more severe strokes) between baseline and 30 days after randomization or 90 days after randomization.","timeFrame":"90 days after randomization"},{"measure":"The proportion of patients with poor quality of life","description":"Poor quality of life defined as EuroQol Five Dimensions Questionnaire (EQ-D5) index score ≤0.5. The EQ-5D index score is measured on a scale of 0 (death) to 1 (full health).","timeFrame":"30 days after randomization"},{"measure":"The proportion of patients with poor quality of life","description":"Poor quality of life defined as EuroQol Five Dimensions Questionnaire (EQ-D5) index score ≤0.5. The EQ-5D index score is measured on a scale of 0 (death) to 1 (full health).","timeFrame":"90 days after randomization"},{"measure":"The proportion of patients with functional independence","description":"Functional independence measured withe BI, which was a commonly used scale for measuring the activity of daily living of people. Score of 10-item scale ranges from 0 (worst) to 100 (best).","timeFrame":"30 days after randomization"},{"measure":"The proportion of patients with functional independence","description":"Functional independence measured withe BI, which was a commonly used scale for measuring the activity of daily living of people. Score of 10-item scale ranges from 0 (worst) to 100 (best).","timeFrame":"90 days after randomization"},{"measure":"Changes in Motor function","description":"Motor function, measured by the Fugl-Meyer Motor Scale (FMMS) score(range from 0-100, with lower score showing worse motor status) change from baseline to 90 days after randomization.","timeFrame":"90 days after randomization"},{"measure":"Changes in Cognitive function","description":"Cognitive function, as measured using the Montreal Cognitive Assessment (MoCA) score (range from 0 to 30, with less than 26 indicating cognitive impairment) change from baseline to 90 days after randomization.","timeFrame":"90 days after randomization"},{"measure":"The proportion of adverse events (AEs)","description":"The proportion of AEs during the treatment.","timeFrame":"90 days after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Acute ischemic stroke patients within 7 days of onset\n* 18 years of age or older, and gender not limited\n* NIHSS score of 4 to 15\n\nExclusion Criteria:\n\n* Secondary stroke caused by a tumor, traumatic brain injury, hematological disease, or other diseases with a confirmed diagnosis\n* Pre-stroke mRS score of more than 1\n* Known severe liver or kidney dysfunction\n* Known allergies for ingredients in the investigational product\n* Known bleeding diathesis or coagulation disorder\n* Known medical condition likely to limit survival to less than 3 months\n* Pregnant women (clinically evident) or breastfeeding women\n* Participation in any investigational study in the previous 3 months\n* Known dementia, uncontrolled psychiatric problems\n* Any condition that could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study. The judgment is left to the discretion of the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Dandan Zhang, PhD, MD","role":"CONTACT","phone":"+8618810532113","email":"zx1zy@126.com"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}